๐
|
Cyclophosphamide versus placebo in scleroderma lung disease.
31 auth.
D. Tashkin,
R. Elashoff,
P. Clements,
J. Goldin,
Michael D. Roth,
Daniel E. Furst,
E. Arriola,
R. Silver,
C. Strange,
M. Bolster,
J. Seibold,
David J. Riley,
V. Hsu,
J. Varga,
Dean E. Schraufnagel,
...
A. Theodore,
R. Simms,
R. Wise,
F. Wigley,
B. White,
V. Steen,
C. Read,
Maureen D Mayes,
E. Parsley,
K. Mubarak,
M. Connolly,
J. Golden,
M. Olman,
B. Fessler,
N. Rothfield,
M. Metersky
|
10 |
2006 |
10 ๐
|
๐
|
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
31 auth.
D. Khanna,
Xiaohong Yan,
D. Tashkin,
D. Furst,
R. Elashoff,
Michael D. Roth,
R. Silver,
C. Strange,
M. Bolster,
J. Seibold,
David J. Riley,
V. Hsu,
J. Varga,
Dean E. Schraufnagel,
A. Theodore,
...
R. Simms,
R. Wise,
F. Wigley,
B. White,
V. Steen,
C. Read,
M. Mayes,
E. Parsley,
K. Mubarak,
M. Connolly,
J. Golden,
M. Olman,
B. Fessler,
N. Rothfield,
M. Metersky,
P. Clements
|
6 |
2007 |
6 ๐
|
๐
|
Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction.
9 auth.
M. Simon,
R. Vanderpool,
M. Nouraie,
T. Bachman,
Pamela M White,
Masataka Sugahara,
...
J. Gorcsan,
E. Parsley,
M. Gladwin
|
6 |
2016 |
6 ๐
|
๐
|
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects
13 auth.
P. Rix,
A. Vick,
N. Attkins,
Geoffrey E. Barker,
A. Bott,
H. Alcorn,
M. Gladwin,
S. Shiva,
Stephen Bradley,
Azra Hussaini,
...
W. Hoye,
E. Parsley,
H. Masamune
|
5 |
2014 |
5 ๐
|
๐
|
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.
15 auth.
C. King,
K. Flaherty,
M. Glassberg,
L. Lancaster,
G. Raghu,
J. Swigris,
Rahul G Argula,
R. Dudenhofer,
N. Ettinger,
J. Feldman,
...
S. Johri,
P. Fernandes,
E. Parsley,
P. Shah,
S. Nathan
|
4 |
2021 |
4 ๐
|
๐
|
Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit
8 auth.
S. Faiz,
S. Faiz,
B. Neale,
E. Rรญos,
T. Campos,
E. Parsley,
...
B. Patel,
Luis Ostrosky-Zeichner
|
4 |
2009 |
4 ๐
|
๐
|
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
55 auth.
J. Casella,
B. Barton,
J. Kanter,
L. V. Black,
S. Majumdar,
A. Inati,
Y. Wali,
R. Drachtman,
M. Abboud,
Y. Kilinรง,
Beng R. Fuh,
M. Al-Khabori,
C. Takemoto,
Emad Salman,
S. Sarnaik,
...
N. Shah,
C. Morris,
J. Keates-Baleeiro,
A. Raj,
Ofelia A Alvarez,
L. Hsu,
A. Thompson,
India Sisler,
B. Pace,
Suzie A Noronha,
Joseph L. Lasky,
Elena Cela de Juliรกn,
K. Godder,
C. Thornburg,
Natalie L. Kamberos,
R. Nuss,
A. Marsh,
William C Owen,
Anne M Schaefer,
C. Tebbi,
C. Chantrain,
D. Cohen,
Z. Karakaล,
C. Piccone,
A. George,
J. Fixler,
T. Singleton,
T. Moulton,
C. Quinn,
Clarisse Lopes de Castro Lobo,
Abdulkareem M. Almomen,
Meenakshi Goyal-Khemka,
P. Maes,
M. Emanuele,
Rebecca T Gorney,
C. Padgett,
E. Parsley,
Shari S. Kronsberg,
G. Kato,
M. Gladwin
|
4 |
2021 |
4 ๐
|
๐ฌ
|
Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes.
R. Hamilton,
E. Parsley,
A. Holian
|
4 |
2004 |
4 ๐ฌ
|
๐ฌ
|
Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOSโข dry powder inhaler device
S. Sahay,
R. Holy,
S. Lyons,
E. Parsley,
Mari Maurer,
Jeffry G Weers
|
3 |
2021 |
3 ๐ฌ
|
๐ฌ
|
Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvasoยฎ in healthy subjects.
R. Roscigno,
T. Vaughn,
E. Parsley,
T. Hunt,
M. Eldon,
L. Rubin
|
2 |
2021 |
2 ๐ฌ
|